Building on the antimicrobial resistance (AMR) joint statement published in 2019, the International Coalition of Medicines Regulatory Authorities (ICMRA) today issued a report that highlights successful regulatory and non-regulatory interventions used in different countries to address the growing public health problem of antimicrobial resistance (AMR).
ICMRA members include medicines regulators from across the world, including the European Medicines Agency and the US Food and Drug Administration.
According to the report, AMR threatens our ability to effectively treat infections because of an ever-increasing range of bacteria and other microorganisms that have adapted to become resistant to available treatments.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze